Adaptive Biotechnologies announced a plan to separate its Minimal Residual Disease (MRD) and Immune Medicine businesses to allow each segment to pursue distinct strategic priorities. Concurrently, the company intends to offer $250 million in convertible senior notes to enhance financial flexibility and support the remaining MRD business.
Key Details
- Business Separation: The company will separate its profitable, commercial-stage MRD business from its discovery-stage Immune Medicine platform. It expects to identify the preferred path for separation by the end of 2026.
- Convertible Notes Offering: Adaptive plans to offer $250 million in convertible senior notes due 2031, with an option for purchasers to acquire an additional $37.5 million.
- Use of Proceeds: Net proceeds will be used to repay the OrbiMed Purchase Agreement for $156.9 million, fund capped call transactions, repurchase up to $25 million of common stock, and for general corporate purposes.